Clinical trials
Cancer (With or Without Metastasis) clinical trials
Below are recruiting cancer (with or without metastasis) clinical trials, each written for real people, not researchers. We’re tracking 13,308 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06832202RecruitingPhase 2
HLX22 plus Enhertu for HR+, HER2-low breast cancer
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07223372Recruiting
Study on male hormone blocking drugs for prostate cancer in Australia
This study looks at how certain drugs (darolutamide, enzalutamide, apalutamide, or abiraterone) that block male hormones are used to treat men with prostate cancer that has spread. It aims to understand real-world treatment patterns in Australia.
Pymble, New South WalesAges 18 years+ - NCT07377084Recruiting
Study of chemicals in head and neck cancer samples
This study looks at the chemical signatures (metabolomics) in blood and tumor tissue from people with head and neck cancer. It aims to find markers that may help predict treatment response or tailor future care.
NiceAges 18 years+ - NCT06531434RecruitingPhase 1/Phase 2
Best treatment plan for advanced esophageal cancer
This trial is for people with T4 esophageal cancer, where the tumor has spread to nearby organs. It aims to find the best treatment approach to improve outcomes.
Tainan, TaiwanAges 18–70 - NCT06531499RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
Los Angeles, CaliforniaAges 18–100 - NCT06533644RecruitingPhase 2
SYNC-T therapy study for advanced prostate cancer
This trial tests a new treatment called SYNC-T Therapy (SV-102) for men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The therapy is given directly into a tumor to help your immune system fight the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06629233Enrolling by invitation
New immunotherapy targets for estrogen-receptor positive breast cancer
This trial tests a new technique to find unique targets on breast cancer cells that could be used for future immunotherapies. It focuses on women with estrogen-receptor positive primary breast cancer.
Ghent, East-FlandersAges 18 years+ - NCT06846437RecruitingPhase 3
New drug JSKN003 vs. Kadcyla for HER2-positive advanced breast cancer
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
ShanghaiAges 18 years+ - NCT07208240RecruitingPhase 1/Phase 2
PSMA-targeted radiation before prostate removal for advanced cancer
This trial tests giving a radioactive drug (PSMA-targeted) before surgery for prostate cancer that has spread locally but not to other parts of the body. The goal is to see if it helps lower the risk of the cancer coming back.
Petah TikvaAges 18 years+ - NCT05742425RecruitingPhase 2
Immunotherapy with chemo and targeted drug for colon cancer in the belly
This Phase 2 trial tests serplulimab (immunotherapy) combined with FOLFIRI chemo plus bevacizumab for colon cancer that has spread to the lining of the abdomen (peritoneal metastases). It aims to shrink these tumors and improve outcomes when surgery can’t fully remove them.
Huzhou, ZhejiangAges 18–75 - NCT05576389RecruitingPhase 2
Fluzoparib plus camrelizumab before surgery for BRCA-related HER2-negative breast cancer
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06843720Recruiting
Easier cervical cancer screening study in Texas
This study tests if offering self-sampling for HPV testing makes it easier for people to get screened for cervical cancer. It is designed for patients at partner clinics in Texas who are due for screening.
Houston, TexasAges 18–65 - NCT06540326RecruitingPhase 2
Second-line therapy for advanced colorectal cancer
This trial tests a combination of chemotherapy with either bevacizumab or cetuximab as a second-line treatment for advanced colorectal cancer. It aims to find which option works better for patients whose first treatment failed.
Hangzhou, ZhejiangAges 18–75 - NCT07198659RecruitingEarly Phase 1
New immune cell therapy for advanced pancreatic cancer
This trial tests a new treatment using your own immune cells (called neutrophils) that are loaded with a drug to fight pancreatic cancer that cannot be removed by surgery. It may be an option if standard treatments have stopped working or caused bad side effects.
Xi’an, ShanxiAges 18–70 - NCT06809933Recruiting
Exercise and movement for gynecologic cancer patients
This study tests whether adding an exercise and activity tracking program can help patients with newly diagnosed gynecologic cancer feel better and handle treatment more easily. You'll wear a Fitbit and get guidance on movement while you go through chemotherapy or surgery.
San Francisco, CaliforniaAges 18 years+ - NCT06866041Recruiting
Prostate cancer markers and imaging for low-risk patients on active surveillance
This trial looks for new markers and advanced scans to better predict which low-risk prostate cancers might grow. If you have low-risk prostate cancer and are managing it with active surveillance, researchers want to see if PSMA-PET scans and tissue markers can give earlier warning of progression.
Milan, ItalyAges 45–80 - NCT06660511RecruitingEarly Phase 1
Combination therapy for HER2-positive platinum-resistant ovarian cancer
This trial tests a combination of two drugs—Disitamab Vedotin and Anlotinib—for patients with ovarian cancer that has come back after platinum chemotherapy. It is designed for people whose tumors show a specific protein called HER2, and it aims to see if the combination is safe and effective.
Changsha, HunanAges 18 years+ - NCT06857305Enrolling by invitationPhase 3
Eribulin every two weeks vs standard schedule for advanced breast cancer
This trial compares a new every-two-week dosing schedule of the chemotherapy drug eribulin to the standard schedule in people with HER2-negative breast cancer that has returned or spread. The goal is to see if the biweekly regimen is safer or works better.
Beijing, BAges 18 years+ - NCT07418437Enrolling by invitation
Loneliness help for cancer survivors
This study tests a program to help reduce loneliness in people who have had cancer. You may be able to join if you often feel lonely and are not currently in a hospital or nursing home.
Seattle, WashingtonAges 18 years+ - NCT07630402Recruiting
Heart Imaging Study for Women With Early Breast Cancer
This study helps doctors find the best way to monitor heart health in women with HER2-positive breast cancer who are receiving a type of targeted chemotherapy. The goal is to catch any heart problems early and keep you safe during treatment.
Rochester, New YorkAges 18–79 - NCT07179757Recruiting
Vulvovaginal cancer treatment study
This study looks at how well treatments like radiation, chemotherapy, or surgery work for people with vulvar or vaginal cancer, and how they affect quality of life. It includes patients treated between 2019 and 2023.
Mumbai, MaharashtraAges Any age - NCT06549907Recruiting
Study of double immunotherapy plus anti-angiogenic therapy
This trial studies people with certain types of colorectal or other solid tumors that did not respond to a single immunotherapy drug. It tests whether adding a second immune checkpoint blocker and an anti-angiogenic drug can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06550687Recruiting
Studying how cancer patients like to learn about genetic results
This trial looks at the best ways to give cancer patients their genetic information before a special test called exome analysis. It aims to make sure you get the information in a way that feels right for you.
DijonAges 18 years+ - NCT05585684Recruiting
Blood test to guide next cancer treatment choices
This study checks whether a blood test can find tumor genetic changes (called “plasma genomic profiling”) to help choose the best next treatment. It may help your care team decide therapy after your cancer progresses or seems likely to progress soon.
Baltimore, MarylandAges 18 years+
Hear when a new Cancer (With or Without Metastasis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer (with or without metastasis)?
- Yes. Clin2 currently lists 13,308 recruiting cancer (with or without metastasis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer (with or without metastasis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer (with or without metastasis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non Small Cell Lung Cancer
- Liver Metastasis Colon Cancer
- Gastric Cancer, Gastroesophageal Junction Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Colorectal Cancer Liver Metastasis
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Leptomeningeal Metastasis of Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.